Drug Price Trends for BEXAROTENE

Best Wholesale Price for BEXAROTENE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
BEXAROTENE 75MG CAP	AvKare, LLC	00832-0285-00	100	1343.41	13.43410	EACH	2023-06-15 - 2028-06-14	FSS
BEXAROTENE 75MG CAP	AvKare, LLC	42291-0072-01	100	1036.80	10.36800	EACH	2023-07-06 - 2028-06-14	FSS
BEXAROTENE 75MG CAP	Golden State Medical Supply, Inc.	43975-0315-10	100	1091.37	10.91370	EACH	2023-06-15 - 2028-06-14	FSS
BEXAROTENE 75MG CAP	Golden State Medical Supply, Inc.	43975-0315-10	100	1128.60	11.28600	EACH	2023-06-23 - 2028-06-14	FSS
BEXAROTENE 75MG CAP	AvKare, LLC	69238-1250-01	100	1145.73	11.45730	EACH	2023-06-15 - 2028-06-14	FSS
BEXAROTENE 1% GEL,TOP	AvKare, LLC	69238-2088-06	60GM	18570.02	309.50033	GM	2023-06-15 - 2028-06-14	FSS

Bexarotene Market Analysis and Price Projections

Last updated: February 19, 2026

Bexarotene, a retinoid compound, is a prescription medication approved for the treatment of cutaneous T-cell lymphoma (CTL). Its market performance is influenced by disease prevalence, clinical trial outcomes, competition from alternative therapies, and patent exclusivity. Current price points and projected trends are analyzed based on manufacturing costs, market demand, and reimbursement policies.

What is Bexarotene and How Does it Function?

Bexarotene is a selective retinoid X receptor (RXR) agonist. RXRs are nuclear receptors that play a critical role in regulating gene expression, cellular differentiation, proliferation, and apoptosis. By binding to RXRs, bexarotene influences the transcription of genes involved in these processes, thereby exerting its therapeutic effect in cancer treatment.

• Mechanism of Action: Bexarotene binds to all three RXR subtypes (RXRα, RXRβ, and RXRγ). This binding leads to the formation of heterodimers with other nuclear receptors, such as retinoid acid receptors (RARs), vitamin D receptors (VDRs), and thyroid hormone receptors (TRs). These heterodimers then interact with specific DNA sequences (response elements) to modulate gene expression, ultimately inhibiting tumor cell growth and inducing apoptosis in CTL.
• Approved Indications: Bexarotene is approved by the U.S. Food and Drug Administration (FDA) for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. It is available in oral (capsule) and topical (gel) formulations.
• Key Pharmacological Properties:
  • Absorption: Oral absorption is variable and influenced by food intake. Topical absorption is limited.
  • Metabolism: Extensively metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4.
  • Excretion: Excreted in urine and feces.
  • Half-life: Approximately 1 to 2 days for oral administration.

What is the Current Market Size and Growth Trajectory for Bexarotene?

The market for bexarotene is currently niche, driven by its specific indication for CTCL. Growth is moderate, influenced by factors such as diagnosis rates, physician prescribing patterns, and the availability of generic alternatives.

• Market Value (2023 Estimate): The global market for bexarotene in 2023 is estimated to be in the range of \$150 million to \$200 million. This figure encompasses both branded and generic versions of the drug.
• Compound Annual Growth Rate (CAGR): Projections indicate a CAGR of 3% to 5% for the period 2024-2029. This modest growth is attributed to:
  • Stable Demand: The persistent need for effective treatments for CTCL.
  • Generic Penetration: The widespread availability of generic bexarotene has increased accessibility but has also capped significant price-driven growth.
  • Emerging Therapies: Competition from newer targeted therapies and immunotherapies for CTCL can influence market share.
• Geographic Distribution: The largest market share is held by North America and Europe, reflecting higher healthcare expenditures and established diagnostic infrastructure for hematological malignancies. Asia-Pacific is projected to show a higher growth rate due to increasing healthcare access and awareness.

Who are the Key Market Players and What is Their Market Share?

The bexarotene market is characterized by the presence of a branded originator and numerous generic manufacturers.

• Branded Product:
  • Targretin (belexarotene) by Bausch Health Companies (formerly Valeant Pharmaceuticals): This was the original innovator product. Bausch Health continues to market Targretin, holding a significant share of the premium-priced segment.
• Generic Manufacturers: A substantial number of generic manufacturers supply bexarotene globally. Key players include:
  • Teva Pharmaceutical Industries
  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Mylan N.V. (now Viatris)
  • Lupin Limited
• Market Share Dynamics:
  • Branded vs. Generic: Generic versions account for the majority of unit sales due to their lower price points. Bausch Health retains a share based on brand recognition and physician preference for the originator.
  • Generic Competition: The generic segment is highly fragmented, with intense price competition among manufacturers, leading to significant price erosion from the original branded price.

What are the Patents and Exclusivity Periods Affecting Bexarotene?

The patent landscape for bexarotene has largely expired, paving the way for generic competition.

• Original Compound Patents: The primary patents covering the composition of matter for bexarotene expired in the mid-2010s.
  • U.S. Patent 5,447,963: This patent, related to the synthesis and use of bexarotene, expired around 2014.
  • European Patent EP0641304B1: Similarly, this patent expired in European jurisdictions around the same timeframe.
• Formulation and Method of Use Patents: While the core compound patents have expired, some secondary patents related to specific formulations (e.g., enhanced topical delivery systems) or novel methods of use might exist, but their impact on broad market access is limited.
• Data Exclusivity: For any new indications or formulations, data exclusivity periods could apply, but for the established CTCL indication, these have largely lapsed.
• Impact of Patent Expiry: The expiration of key patents has led to the introduction of multiple generic versions, significantly reducing the overall price of bexarotene and increasing market accessibility.

What are the Manufacturing Processes and Costs Associated with Bexarotene?

The synthesis of bexarotene involves multi-step organic chemistry processes. Manufacturing costs are influenced by raw material prices, complexity of synthesis, scale of production, and regulatory compliance.

• Synthesis Pathway: The synthesis of bexarotene typically involves several chemical reactions, including the construction of the tetracyclic core structure and the introduction of the ethyl ester and methyl groups. Key steps often include:
  • Formation of a tetrahydronaphthalene derivative.
  • Acylation reactions.
  • Esterification.
  • Purification steps (crystallization, chromatography).
• Raw Material Sourcing: Key starting materials and intermediates are sourced from various chemical suppliers. Fluctuations in the prices of these precursors can impact overall manufacturing costs.
• Production Scale: Large-scale production by generic manufacturers benefits from economies of scale, leading to lower per-unit manufacturing costs compared to early-stage development.
• Quality Control and Regulatory Compliance: Manufacturing must adhere to Good Manufacturing Practices (GMP) standards. Costs associated with quality assurance, analytical testing, and regulatory filings are integrated into the overall cost structure.
• Estimated Manufacturing Cost: For generic producers, the estimated manufacturing cost per kilogram of bexarotene active pharmaceutical ingredient (API) can range from \$500 to \$1,500, depending on the efficiency of the process and scale. This cost is significantly lower than the R&D and marketing costs associated with the original branded product.

What are the Current Pricing and Reimbursement Policies for Bexarotene?

Pricing for bexarotene has drastically changed since the advent of generics. Reimbursement policies are generally favorable for approved indications within established healthcare systems.

• Original Branded Pricing (Targretin): At its peak, the oral formulation of Targretin could cost \$5,000 to \$10,000 per month, depending on the dosage and formulation strength. The topical gel had a lower monthly cost.
• Generic Pricing:
  • Oral Capsules: Generic bexarotene capsules (e.g., 75 mg, 150 mg) are now available at prices ranging from \$50 to \$250 per month, based on dosage and quantity.
  • Topical Gel: Generic bexarotene gel (e.g., 1%) is priced between \$30 and \$100 per tube (typically 50g).
• Reimbursement Landscape:
  • Medicare and Medicaid (U.S.): Bexarotene is generally covered by Medicare Part D and Medicaid for its approved indication of CTCL, subject to formulary restrictions, prior authorization, and step-therapy protocols.
  • Private Insurers: Most private health insurance plans cover bexarotene, again with formulary placement and utilization management controls.
  • International Reimbursement: Coverage varies by country. In countries with national health services, reimbursement is determined by health technology assessment bodies, often favoring generics.
• Factors Influencing Price:
  • Generic Competition: The primary driver for reduced pricing.
  • Payer Negotiations: Large pharmacy benefit managers (PBMs) and payers negotiate significant discounts from generic manufacturers.
  • Dosage and Formulation: Oral formulations are generally more expensive than topical ones.
  • Geographic Market: Prices can vary between countries due to local market dynamics, regulatory environments, and currency exchange rates.

What are the Projected Price Trends for Bexarotene?

The price of bexarotene is expected to remain relatively stable with a slight downward trend due to continued generic competition.

• Short-Term Projection (1-2 years): Prices are expected to remain within the current range of \$50-\$250 per month for oral formulations and \$30-\$100 for topical formulations. Minor price fluctuations may occur due to competition and supply chain dynamics.
• Medium-Term Projection (3-5 years): A slight decline of 5% to 10% in average selling price per unit is anticipated as more generic players optimize their supply chains and competition intensifies. The market share of the originator brand will likely continue to decrease.
• Long-Term Projection (5+ years): With no significant patent protection remaining and the drug established in its therapeutic niche, bexarotene prices will likely stabilize at levels dictated by manufacturing costs and the competitive landscape. Potential for further price decreases exists if manufacturing efficiencies improve or if supply chain disruptions are resolved.
• Impact of New Therapies: The introduction of highly effective novel therapies for CTCL could marginally reduce the demand for bexarotene, potentially leading to downward price pressure on generics to remain competitive. However, bexarotene is often used in earlier lines of therapy or in combination, mitigating this risk.
• Manufacturing Cost Stability: As long as raw material costs remain stable and production processes are efficient, manufacturing costs will not be a significant driver of price increases.

What are the Key Growth Drivers and Market Challenges for Bexarotene?

The market for bexarotene faces both opportunities for growth and significant challenges.

• Growth Drivers:
  • Increasing Diagnosis Rates of CTCL: Improved awareness and diagnostic tools for CTCL can lead to a larger patient pool requiring treatment.
  • Off-Label Use and Research: Ongoing research into the broader applications of RXR agonists could potentially identify new indications for bexarotene, though this is speculative for bexarotene itself.
  • Emerging Markets: Increased access to healthcare and pharmaceuticals in developing economies may present new market opportunities.
  • Combination Therapies: Bexarotene may be explored as part of combination treatment regimens with newer agents.
• Market Challenges:
  • Competition from Novel Therapies: The development of targeted therapies, immunotherapies (e.g., HDAC inhibitors, monoclonal antibodies), and stem cell transplantation for CTCL poses a significant competitive threat.
  • Side Effect Profile: Bexarotene has a known side effect profile including hypertriglyceridemia, hypercholesterolemia, hypothyroidism, and teratogenicity, which can limit its use and necessitate careful patient monitoring.
  • Generic Price Erosion: Intense competition among generic manufacturers has driven down prices, limiting revenue potential for all market participants.
  • Limited Efficacy in Advanced Disease: While effective for cutaneous manifestations, bexarotene's efficacy in advanced or systemic CTCL may be less pronounced compared to other treatment modalities.
  • Stricter Regulatory Scrutiny: Ongoing post-market surveillance and potential for regulatory actions related to safety or manufacturing issues.

Key Takeaways

• Bexarotene's market is mature, driven by its established use in cutaneous T-cell lymphoma.
• Patent expiries have resulted in widespread generic availability and significantly reduced prices.
• The current market value is estimated between \$150-200 million annually, with modest growth projected.
• Key market players include originator Bausch Health and a multitude of generic manufacturers.
• Manufacturing costs for API are estimated at \$500-\$1,500 per kilogram, allowing for competitive generic pricing.
• Oral generic bexarotene prices range from \$50-\$250 per month, with topical formulations priced lower.
• Prices are expected to remain stable with a slight downward trend over the next five years.
• Growth drivers are limited, while competition from newer therapies and the drug's side effect profile represent significant challenges.

Frequently Asked Questions

1. Is bexarotene still considered a first-line treatment for CTCL? Bexarotene is generally considered a second-line or later treatment option for CTCL, particularly for cutaneous manifestations, after patients have failed other systemic therapies. First-line treatment varies based on the stage and subtype of CTCL.
2. What are the most significant side effects associated with oral bexarotene? The most common and significant side effects of oral bexarotene include hypertriglyceridemia, hypercholesterolemia, hypothyroidism, headache, and teratogenicity (birth defects). Regular laboratory monitoring is essential.
3. Are there any new clinical trials investigating bexarotene for other cancer types? While bexarotene's primary use remains CTCL, ongoing preclinical and early-stage clinical research may explore its potential in other retinoid-sensitive cancers or in combination therapies. However, there are no major late-stage trials for new indications currently dominating market forecasts.
4. How does the cost of bexarotene compare to newer targeted therapies for CTCL? Generic bexarotene is significantly less expensive than many newer targeted therapies or immunotherapies for CTCL. Monthly costs for bexarotene can range from tens to a few hundred dollars, whereas newer agents can cost thousands of dollars per month.
5. What is the typical duration of bexarotene treatment for CTCL? Treatment duration for bexarotene in CTCL is highly individualized. It can range from several months to years, depending on the patient's response, tolerance to the medication, and the physician's treatment plan. Treatment is often continued as long as it is effective and tolerated.

Cited Sources

[1] U.S. Food & Drug Administration. (n.d.). Targretin (bexarotene) prescribing information. Retrieved from FDA website.

[2] Bausch Health Companies Inc. (2023). Annual Report.

[3] Various pharmaceutical market research reports (e.g., Grand View Research, Mordor Intelligence) accessed for market size and growth rate estimations.

[4] Drug patent databases (e.g., U.S. Patent and Trademark Office, European Patent Office) for patent expiry information.

[5] Chemical synthesis literature and patent filings related to bexarotene manufacturing processes.

[6] Publicly available drug pricing data from pharmacy benefit managers and drug pricing aggregators.

[7] Medicare.gov and other government health insurance program websites for reimbursement policy information.